Background: A comprehensive real-world analysis of residual risk factors for recurrent major adverse cardiovascular events (MACE) following hospital admission for acute coronary syndrome (ACS) is lacking. The objectives of this study were: 1) to describe population trends for outcomes, risk factors, and medication prescribing patterns post-ACS and 2) to identify factors associated with recurrent MACE. Methods: A retrospective cohort study of 4,884 post-ACS patients admitted at a large integrated healthcare system between 2015-2021 was performed to investigate the relationship between recurrent MACE (ACS, cerebrovascular events, all-cause mortality, and unplanned revascularization), modifiable risk factor trends, and medical therapy prescribing patterns. Patients were separated into 2 cohorts based upon whether they experienced recurrent MACE following the initial hospitalization. Data were obtained via programmatic extraction from the electronic health record. Descriptive statistics were performed. Generalized linear models were used to assess risk factor trends and pairwise comparisons were performed between time points. Results: Median length of follow-up after ACS was 31.2 months. Recurrent MACE occurred in 28% of patients. Despite 95.9% of all patients receiving prescriptions for high-intensity statins, >40% did not achieve LDL-C goal of <70 mg/dL, and only 11.6% and 2.6% of all patients were prescribed ezetimibe or proprotein convertase subtilisin kexin type 9 inhibiting monoclonal antibodies, respectively. Although >30.0% of patients had triglycerides ≥150 mg/dL at all time points, ≤6% were prescribed any non-statin triglyceride lowering therapy and 0.6% were prescribed icosapent ethyl. Persistent hypertriglyceridemia (≥150 mg/dL) was associated with recurrent MACE at 6-, 12-, and 24-months post-ACS (p<0.05), and the relative risk ranged between 1.20-1.35 at those timepoints. Conclusions: This study demonstrates the need for more comprehensive post-ACS care to address residual cardiometabolic risk factors and suboptimal prescribing patterns for indicated therapies. Targeted strategies are needed to address hypertriglyceridemia for cardiovascular risk reduction.

Laney K. Jones is a consultant for Novartis. Scott LeMaire serves as a consultant for Cerus and has served as a principal investigator for clinical studies sponsored by Terumo Aortic and CytoSorbents. Shikhar Agarwal serves as a proctor for Edwards Lifesciences and as a speaker for Abbott Laboratories and Medtronic, Inc. Stephen J. Voyce receives study funding from Astra Zeneca and Amarin Pharma, Inc.

This research received funding from Amarin Pharma, Inc.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The internal review board (IRB# 2021-0667) of Geisinger Medical Center in Danville, PA waived ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

The data that support the findings of this study are available from the corresponding author upon reasonable request. The first and corresponding author had full access to all data in the study and take responsibility for its integrity and data analysis.